Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 11/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.35 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.34 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.34 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.34 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.34 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29209039 | 0.79 | MTOR (0.47) | MTORPIK3CAMAP3K12PIK3CBPIK3CG | |
| SCHEMBL20476215 | 0.77 | GRIN2D (0.45) | MTORPIK3CAMAP3K12OGASOS1 | |
| SCHEMBL18128074 | 0.77 | MTOR (0.31) | MTORPIK3CA | |
| SCHEMBL24757838 | 0.76 | MAP3K12 (0.35) | MAP3K12OGA | |
| SCHEMBL15058900 | 0.76 | AOC3 (0.38) | OGA | |
| SCHEMBL20476237 | 0.74 | ALDH1A1 (0.40) | — | |
| SCHEMBL31177641 | 0.72 | MAP3K12 (0.34) | MTORPIK3CAMAP3K12OGA | |
| SCHEMBL25147416 | 0.72 | MTOR (0.40) | MTORPIK3CAMAP3K12RICTORRPTOR | |
| SCHEMBL25147414 | 0.72 | MTOR (0.40) | MTORPIK3CAMAP3K12RICTORRPTOR | |
| SCHEMBL15725788 | 0.72 | PTPN11 (0.49) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3583105-B1 | PYRROLO [1,2-B]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| WO-2018152368-A1 | PYRROLO [1,2-B] PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2018-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | SDHB, CYP4F2, CYP1B1 | MTOR 2667/4885PIK3CA 2990/4885MAP3K12 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.